Milestone Pharmaceuticals Net Income
| MIST Stock | USD 1.65 0.08 4.62% |
As of the 4th of March, Milestone Pharmaceuticals secures the Risk Adjusted Performance of (0.12), mean deviation of 2.74, and Standard Deviation of 4.01. In connection with fundamental indicators, the technical analysis model lets you check existing technical drivers of Milestone Pharmaceuticals, as well as the relationship between them.
Analyzing historical trends in various income statement and balance sheet accounts from Milestone Pharmaceuticals' financial statements helps investors evaluate the company's valuation, profitability, and current liquidity needs. Key fundamental drivers impacting Milestone Pharmaceuticals' valuation are summarized below:Milestone Pharmaceuticals does not presently have any fundamental ratios for analysis. This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools. Milestone | Build AI portfolio with Milestone Stock |
Is there potential for Pharmaceuticals market expansion? Will Milestone introduce new products? Factors like these will boost the valuation of Milestone Pharmaceuticals. Expected growth trajectory for Milestone significantly influences the price investors are willing to assign. Understanding fair value requires weighing current performance against future potential. All the valuation information about Milestone Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Investors evaluate Milestone Pharmaceuticals using market value (trading price) and book value (balance sheet equity), each telling a different story. Calculating Milestone Pharmaceuticals' intrinsic value - the estimated true worth - helps identify when the stock trades at a discount or premium to fair value. Analysts utilize numerous techniques to assess fundamental value, seeking to purchase shares when trading prices fall beneath estimated intrinsic worth. External factors like market trends, sector rotation, and investor psychology can cause Milestone Pharmaceuticals' market price to deviate significantly from intrinsic value.
Understanding that Milestone Pharmaceuticals' value differs from its trading price is crucial, as each reflects different aspects of the company. Evaluating whether Milestone Pharmaceuticals represents a sound investment requires analyzing earnings trends, revenue growth, technical signals, industry dynamics, and expert forecasts. Conversely, Milestone Pharmaceuticals' market price signifies the transaction level at which participants voluntarily complete trades.
Milestone Pharmaceuticals 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Milestone Pharmaceuticals' stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Milestone Pharmaceuticals.
| 12/04/2025 |
| 03/04/2026 |
If you would invest 0.00 in Milestone Pharmaceuticals on December 4, 2025 and sell it all today you would earn a total of 0.00 from holding Milestone Pharmaceuticals or generate 0.0% return on investment in Milestone Pharmaceuticals over 90 days. Milestone Pharmaceuticals is related to or competes with Rani Therapeutics, Molecular Partners, Cardiff Oncology, Elicio Therapeutics, Innate Pharma, Corbus Pharmaceuticals, and Cassava Sciences. Milestone Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of cardiov... More
Milestone Pharmaceuticals Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Milestone Pharmaceuticals' stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Milestone Pharmaceuticals upside and downside potential and time the market with a certain degree of confidence.
| Information Ratio | (0.18) | |||
| Maximum Drawdown | 28.79 | |||
| Value At Risk | (6.38) | |||
| Potential Upside | 4.88 |
Milestone Pharmaceuticals Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Milestone Pharmaceuticals' investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Milestone Pharmaceuticals' standard deviation. In reality, there are many statistical measures that can use Milestone Pharmaceuticals historical prices to predict the future Milestone Pharmaceuticals' volatility.| Risk Adjusted Performance | (0.12) | |||
| Jensen Alpha | (0.74) | |||
| Total Risk Alpha | (0.88) | |||
| Treynor Ratio | (0.48) |
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Milestone Pharmaceuticals' price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Milestone Pharmaceuticals March 4, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | (0.12) | |||
| Market Risk Adjusted Performance | (0.47) | |||
| Mean Deviation | 2.74 | |||
| Coefficient Of Variation | (585.53) | |||
| Standard Deviation | 4.01 | |||
| Variance | 16.09 | |||
| Information Ratio | (0.18) | |||
| Jensen Alpha | (0.74) | |||
| Total Risk Alpha | (0.88) | |||
| Treynor Ratio | (0.48) | |||
| Maximum Drawdown | 28.79 | |||
| Value At Risk | (6.38) | |||
| Potential Upside | 4.88 | |||
| Skewness | (1.14) | |||
| Kurtosis | 5.79 |
Milestone Pharmaceuticals Backtested Returns
Milestone Pharmaceuticals has Sharpe Ratio of -0.17, which conveys that the firm had a -0.17 % return per unit of risk over the last 3 months. Milestone Pharmaceuticals exposes twenty-three different technical indicators, which can help you to evaluate volatility embedded in its price movement. Please verify Milestone Pharmaceuticals' Risk Adjusted Performance of (0.12), mean deviation of 2.74, and Standard Deviation of 4.01 to check out the risk estimate we provide. The company secures a Beta (Market Risk) of 1.44, which conveys a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Milestone Pharmaceuticals will likely underperform. At this point, Milestone Pharmaceuticals has a negative expected return of -0.68%. Please make sure to verify Milestone Pharmaceuticals' jensen alpha, skewness, as well as the relationship between the Skewness and day typical price , to decide if Milestone Pharmaceuticals performance from the past will be repeated at some point in the near future.
Auto-correlation | 0.80 |
Very good predictability
Milestone Pharmaceuticals has very good predictability. Overlapping area represents the amount of predictability between Milestone Pharmaceuticals time series from 4th of December 2025 to 18th of January 2026 and 18th of January 2026 to 4th of March 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Milestone Pharmaceuticals price movement. The serial correlation of 0.8 indicates that around 80.0% of current Milestone Pharmaceuticals price fluctuation can be explain by its past prices.
| Correlation Coefficient | 0.8 | |
| Spearman Rank Test | 0.74 | |
| Residual Average | 0.0 | |
| Price Variance | 0.02 |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
Based on the recorded statements, Milestone Pharmaceuticals reported net income of (41.52 Million). This is 112.17% lower than that of the Pharmaceuticals sector and 159.27% lower than that of the Health Care industry. The net income for all United States stocks is 107.27% higher than that of the company.
Milestone Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Milestone Pharmaceuticals' direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Milestone Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Milestone Pharmaceuticals by comparing valuation metrics of similar companies.Milestone Pharmaceuticals is currently under evaluation in net income category among its peers.
Milestone Fundamentals
| Return On Equity | -2.61 | ||||
| Return On Asset | -0.42 | ||||
| Current Valuation | 121.11 M | ||||
| Shares Outstanding | 85.17 M | ||||
| Shares Owned By Insiders | 3.31 % | ||||
| Shares Owned By Institutions | 41.97 % | ||||
| Number Of Shares Shorted | 7.47 M | ||||
| Price To Earning | (4.44) X | ||||
| Price To Book | 7.15 X | ||||
| Price To Sales | 77.32 X | ||||
| EBITDA | (37.83 M) | ||||
| Net Income | (41.52 M) | ||||
| Cash And Equivalents | 86.24 M | ||||
| Cash Per Share | 2.87 X | ||||
| Total Debt | 54.8 M | ||||
| Debt To Equity | 0.01 % | ||||
| Current Ratio | 21.26 X | ||||
| Book Value Per Share | 0.20 X | ||||
| Cash Flow From Operations | (28.85 M) | ||||
| Short Ratio | 3.27 X | ||||
| Earnings Per Share | (0.79) X | ||||
| Target Price | 6.6 | ||||
| Number Of Employees | 33 | ||||
| Beta | 0.54 | ||||
| Market Capitalization | 140.53 M | ||||
| Total Asset | 75.5 M | ||||
| Retained Earnings | (367.55 M) | ||||
| Working Capital | 65.8 M | ||||
| Current Asset | 110.42 M | ||||
| Current Liabilities | 7.17 M | ||||
| Net Asset | 75.5 M |
About Milestone Pharmaceuticals Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Milestone Pharmaceuticals's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Milestone Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Milestone Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Milestone Stock Analysis
When running Milestone Pharmaceuticals' price analysis, check to measure Milestone Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Milestone Pharmaceuticals is operating at the current time. Most of Milestone Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Milestone Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Milestone Pharmaceuticals' price. Additionally, you may evaluate how the addition of Milestone Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.